Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 24

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 24
---
 may also supplement, update or amend information contained in this
document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this
prospectus or any prospectus supplement, carefully before you invest.

Our securities may be sold directly by us to you,
through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale,
you should refer to the section titled “Plan of Distribution” in this prospectus and in the applicable prospectus supplement.
If any underwriters or agents are involved in the sale of our securities with respect to which this prospectus is being delivered, the
names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options will be set forth in
a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will
also be set forth in a prospectus supplement.

Our common stock is listed on the Nasdaq Capital
Market, under the symbol “DERM.” As of November 1, 2022, the aggregate market value of our public float, calculated according
to General Instructions I.B.6. of Form S-3, is $17,467,322.17, based on 11,765,700 shares of common stock outstanding as of December 28,
2022, of which 7,308,503 shares of our common stock are held by non-affiliates. We have not offered any securities pursuant to General
Instruction I.B.6. of Form S-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus. Pursuant
to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding
more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000.

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page 5 of this prospectus under the caption “ Risk Factors.” We may include specific risk factors in supplements to this prospectus under the caption “ Risk Factors.” This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities